1 / 45

International Mouse Phenotyping Consortium & MRC MOUSE NETWORK Tom Weaver Director, MRC Harwell Mary Lyon Centre

International Mouse Phenotyping Consortium & MRC MOUSE NETWORK Tom Weaver Director, MRC Harwell Mary Lyon Centre. Outline. Update on the IMPC Progress Alleles & Gene Selection Production Phenotyping MRC Mouse Network Objectives Expectations Some Ideas For Going Forward.

delilah
Download Presentation

International Mouse Phenotyping Consortium & MRC MOUSE NETWORK Tom Weaver Director, MRC Harwell Mary Lyon Centre

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. International Mouse Phenotyping Consortium & MRC MOUSE NETWORK Tom Weaver Director, MRC Harwell Mary Lyon Centre

  2. Outline • Update on the IMPC Progress • Alleles & Gene Selection • Production • Phenotyping • MRC Mouse Network • Objectives • Expectations • Some Ideas For Going Forward

  3. Vision For Next 10 Years... • An Encyclopaedia of Mammalian Gene Function • Create KO mice for ALL GENES • Database with associated primary phenotype info; • Discover unforeseen gene function; • Free and unfettered access to MICE • Free thousands of researchers from tool generation; • A rich seam for future hypothesis driven research, with the potential for breakthrough discoveries; • A transformative project that will underpin the future of biomedical science and the biology of disease systems.

  4. 22 Partners, 13 Production Centres, 9 Countries www.mousephenotype.org

  5. IMPC Activities • Undertake broad based primary phenotyping of 20,000 mutants from the IKMC resource • A coordinated effort of mouse clinics worldwide • Phase I (2011-2016): phenotype up to 5,000 lines • Pipeline development, logistics • Phenotyping technology developments e.g. imaging • Ramp up • Phase II (2016-2021): Phenotype 15,000 mutants • Data freely available through a Data Coordination Centre, supported by R&D groups at clinics

  6. Value of Program • Scientific (Hypothesis Generating) • Innovation Bottleneck (SGX) • Welfare (NC3R) • Financial (Funders) • Paradigm Shift in Scientific Culture (MRC MOUSE NETWORK)

  7. Traditional “One Gene at a Time” Approach Clone the Gene Knock It Out in Cells Create A Mouse Study Effect Publish Your Work Share with Other Labs • 1 Gene, 1 Mutation, 1 Mouse • 3-5 Year Investment in Time and Resources • Expensive & Inefficient • Individual Scientist Driven

  8. Alternative “Whole Genome” Approach Sequence the Genome Mutate EVERY gene Create a Repository of Mice Study Effect “Phenotype” Data Release Share Mice with Other Scientists Study Effect “Phenotype” Publish Work • All Genes, 20K Mutations and Mouse Strains • Highly Parallel (HTP “Factories”) • Immediate Access & Sharing • Cost Effective • Global Networks Required

  9. Status: Raised $200M for Phase 1 Launch – Sept 28th 2011

  10. New Homepage for IMPC Portal (Andy Blake) www.mousephenotype.org

  11. IMPC Operational Plan

  12. Key Team Players @ HarwellThey Will Deliver This Project Martin F. Lydia T. Deen Q. Sara W. Tertius H. Michael C. Mark G. Production LacZ Profiling Cohort Breeding Necropsy Quality Assurance Archiving Allele QC Phenotyping Pathology Distribution Genotyping Histology Training LIMS, Data Portal & Bioinformatics Andy B. Alison W. Hugh M. Annie M. Finance, HR, Engagement Liz M. Hilary G. Nanda R.

  13. MOUSE PRODUCTION STATUS

  14. IKMC Alleles(will be used in IMPC) • Knockout-first, conditional ready allele: • Promoter-driven selection cassette Francis Stewart (Dresden) Allan Bradley and Bill Skarnes (WTSI)Wolfgang Wurst (Helmholtz) See Skarnes et al. Nature 474, 262-263 (2011)

  15. STATUS: From Mouse Production to Cryopreservation • Gene selection • Gene selection, and tracking from ES QC to MI, iMits successfully launched • MRC STRATEGY: MMN SELECTION • Delivery of ES Cells • KOMP Repository and EUMMCR • tm1a=> tm1b allele conversion • Different approaches will be applied across IMPC centres (Harwell Actin-CRE working well) • Cryopreservation strategy • tm1a (and tm1b) – sperm freezing

  16. IKMC Alleles(will be used in IMPC) • Knockout-first, conditional ready allele: • Promoter-driven selection cassette We Archive & Distribute These Strains We Phenotype, Archive & Distribute These Strains Conditional Allele Requires Breeding Francis Stewart (Dresden) Allan Bradley and Bill Skarnes (WTSI)Wolfgang Wurst (Helmholtz) See Skarnes et al. Nature 474, 262-263 (2011)

  17. Harwell Production Status • 444 MMN Genes “Assigned” to MRC and in progress (BaSH & MRC) =>assume 220 GLTS (50% Pass Rate) • 53 tm1a alleles (legacy/imported) undergoing cre-deletion • 88 Genes Received as ES cells • 9 GLTs: first one is “IGF1R” • 6 months from MI to access

  18. NEUROMOUSE Gene List & SynergiesSee Handout • Progress • 28 genes in progress • 5 ES cells in Allele QC, rest awaiting receipt! • Genes “Overlapping” interest with other members of network • 5 with other consortia • Neuodegenerative disease and aging, cancer, Development, Vision, Respiratory • Synergy w/ Other Production Centres • E.g. we nominate, they KO =>50 lines with China (MADD) • 8 Genes from NEUROMOUSE (JAX, TCP, ICS,…)

  19. PHENOTYPING STATUS

  20. Phenotyping Program Has Evolved…. Much Discussion • Build on EUMODIC, MGP, NIH K312 • Focus Groups • Surveys • Operational Workshops (London, Toronto, Barca) • Munich, Nov 2011

  21. IMPC Adult Phenotyping Pipeline + LacZ Reporter 23 platforms, 100’s of parameters/metadata

  22. Protocol Development Working Groups ABR Body Composition/ X-ray Slit lamp/ Ophthalmoscope Hematology/Clin Chem/Insulin Heart Wt./Gross Pathology/Block Banking FACS, IGs • LacZ • Fertility & Viability • SHIRPA/Dysmorphology • Open Field • Grip Strength/Startle, PPI • ECG/Echo • Calorimetry/IPGTT IMPReSS – International Mouse Phenotyping Resource of Standardised Screens

  23. IMPReSS(Annie Mallon)Now Live www.mousephenotype.org/impress • Data Wranglers • Protocols and Parameters for 13 Platforms • Uploaded to the IMPReSS database • In process of organizing calls for other SOPs • SEE HANDOUT

  24. Phenotyping Progress @ MRC(Sara Wells & Tertius Hough) • Recruiting & Reorg Complete (breeding stations), All Equipment In place • SOPs Complete For Agreed Tests (MASSIVE TASK!) • Pilot data for echo/ultrasound, challenge plethysmography, ABR • 31 TM1A alleles cre-deletion underway (Tm1B) • 12 TM1B alleles in cohort production, first full cohort started this month. • Data will be in INTERPHENOME

  25. INTERPHENOME • Mouse • Phenotyping • Informatics • Infrastructure • “MPI2” • Harwell, Sanger, EBI (Pilot: www.europhenome.org)

  26. EuroPhenome (Annie Mallon)(www.europhenome.org) 26,258 mice 8.22M data points 3,416 annotations

  27. Gene and Phenotype Search Tools

  28. Complex Phenotype Search Result“Increased Circulating Cholesterol” AND “Increased Circulating LDL Cholesterol”

  29. EuroPhenomeHeatmaps

  30. New phenotypes revealed(Steve Brown) • Srsf4 (serine/arginine-rich splicing factor 4) • Not annotated in MGI • Pipeline Screening: Annotations in different systems • Reduced RBC count, haemoglobin concentration, haematocrit across sexes and zygosities • Much lower Grip Strength in both sexes • More subtle changes in Calorimetry and Opthalmoscope • 74% (131/176) genes with no prior annotations had significant phenotypes

  31. Pipeline Under Constant Review(Role for Networks) Number of Annotations per top level ontology term cardio lung

  32. Distribution of Phenotype Annotations Viability • 84% of lines have an annotation including viability and fertility

  33. Proposed IMPC Embryonic Lethal Phenotyping Pipeline IKMC mES cells (B6N) ≥7 Embryos from Sub-viable Lines Germline transmission subviable Dissection & gross morphology (embryos & placentae) Dissection & gross morphology (embryos & placentae) Heterozygotes Homozygotes viable <40% expected homozygous mutants at weaning Histopathology (embryos & placentae) lacZ staining (embryos & placentae) Embryo μCT (iodine staining) Homozygotes E14.5 >40% expected homozygous mutants at weaning E12.5 viable Adult Phenotyping Pipeline Draft Pipeline – Under Consultation

  34. IMPC & InfraComp Workshop on Embryonic Lethal Screening • Two Day Workshop: April 18th-19th, 2012; Institute of Child Health, UCL • Organizers: Andy Copp (UCL, UK), Janet Rossant(Univ Toronto, Canada), Tom Weaver (Harwell, UK), Tim Mohun(NIMR, UK), Monica Justice (Baylor, USA), Michael Raess(HMGU, Germany) • Goal: Agree a consensus strategy for embryonic phenotyping & LacZ analysis • Topics: • Scientific Value of Embryology to Research Community • Current Status of Screening – Don’t reinvent the wheel, Funding opportunities • Operational Workflow – Not One Single Pipeline, Best Fits • LacZ Reporter Analysis – Agree Pipeline • Information Technology & Annotation Dev Consortia Input Critical FIRST MAJOR CONTRIBUTION FROM MRC MOUSE NETWORK

  35. Engagement Plan:MRC Mouse Network • MRC Mouse Network Will Be a Forum to: • Communicate about IMPC • Encourage Uptake of Resources • Promote Use of Resource • Facilitate Collaboration • 16 Consortia Formed • 7/10 Top Therapeutic Areas • >400 PIs/25% Clinical • “MADD” Consortium Example • Novel Drug Target Class • 100 Knock Outs • Structures/Assays/Industry Collaboration

  36. Consortium Principal Investigator Bone and Cartilage Raj Thakker, Oxford Cardiovascular Patricia Munroe, QMU Development Andrew Copp, UCL Drug Targets: UK-China (MADD) Dario Alessi, Dundee Haematopoiesis and Cancer Claus Nerlov, Edinburgh Host Response to Pneumonia Peter Andrews, Leicester Immune System Werner Muller, Manchester Innate Immunity David Hume, Edinburgh Liver Disease (UK Gold) Raj Thakker, Oxford Models of Diabetes and Obesity (MODO) Tony Vidal-Puig; Anthony Coll, Camb Neurodegenerative Disease & Aging (nPad) Jean Manson, Edinburgh Neuromouse Kay Davies, Oxford; Lizzy Fisher, Prion/UCL Opthamology Ian Jackson, Edinburgh; Marcela Vertruba, Cardiff Renal (RUMP) Robert Unwin, KCL; Matthew Bailey, Edinburgh Respiratory Charlotte Dean, Matthew Hind, Imperial Tissue Recomdelling and Fibroblast Disease (TiReFiC) Chirs Buckley, Birmingham; Jill Norman, UCL Network Consortia 16 Consortia Network; Met January at Harwell

  37. Ambitions For Network • Promote IMPC and Mouse Models: • facilitate more road shows, participate in training course(s) • Proactive Discussion/Planning: • Assign a “Champion” to be main contact with Harwell. Simplify, streamline the communication (gene lists, issues, ideas). Updated/Revised Plan in April. • Encourage the network to evolve so that individuals can work together rather than simple info flow from Harwell/Pis. Use the portal as a project management/coordination tool. • Direct Participation: Actions with Added Value to Program • Pilot Work: Kick-start secondary phenotyping • Active Uptake of Lines/Data • Feedback: • We will ask for a report at end of first year (spring 2013), will influence development of the program. • USER CASE SCENARIO => DATA PORTAL

  38. On-line Portal(mrcmousenetwork.har.mrc.ac.uk) • Individual members of the MRC Mouse Network will be able to communicate directly to one another in a manner similar to “Facebook”

  39. Key Functionalities • Important Functions • Secure Log in (already registered!) • General Information • News • Events • Forum => Incredibly Useful for IMPC • Nov 2008, 156 Active Users, 24 Forums, 300 Forum Threads, 8K page views…. • My Consortium • All Consortia • Demo From Andy Blake Today

  40. Training For Networks • The Network will promote training in the form of workshops, training courses, and site visits. • Mouse Genome Browsing, Mutant Mouse Resources • Customize to MMN • Develop Case Studies, eg GWAS => Candidates => Resources Available • 2/3 WEEK OF May 2012, Harwell, 20-40 People

  41. Please Update Your Action Plan This Month (Hilary will Email Pis) • Champion. Need to get your contact actively linked with our scientists. Hilary/Tom can help coordinate. • Access to Mice/Samples. Need feedback and start planning now, but be realistic. Your plans for 2’/3’ phenotyping. • Primary Phenotyping Data. Help to evaluate. Use case input. • Pathology Network. Cross cutting need. Recruiting a senior pathologist to lead. Join our network? • Conditional Alleles. Service will be available. Are you interested? • Coordinate Funding. Opportunities to look for technical support, pilots, etc… BHF example.

  42. Harwell has an immediate need for an Experienced Pathologist (Permanent B2, sr. lecturer equivalent)Role is to lead the program in animal health and welfare, as well as have overall responsibility for pathology services strategy and management at the Mary Lyon Centre. Opportunity for international collaboration in pathology phenotyping and annotation. Please Contact: Tom Weaver, t.weaver@har.mrc.ac.uk +44(0)778-0666-0922

  43. MRC Mouse Network Timeline of Activity

  44. SUMMARY • KEY INFO PORTALS: • IMPC: http://www.mousephenotype.org • MRC MOUSENETWORK PORTAL • WEB: http://mrcmousenetwork.har.mrc.ac.uk • Email Contact: mrcmousenetwork@har.mrc.ac.uk • Harwell Contacts Who Can Help • Tom Weaver: t.weaver@har.mrc.ac.uk • Andy Blake: a.blake@har.mrc.ac.uk • Hilary Gates: h.gates@har.mrc.ac.uk

  45. Thank You

More Related